{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-098380","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.310589+00:00","generated_at":"2026-05-30T00:31:11.837820+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio completes randomization of 208 patients in Phase 2 Alzheimer's trial; top-line data Q2 2025","bullets":["Total of 208 patients enrolled, exceeding target; 56% mild AD and 44% MCI.","Top-line cognitive results expected in Q2 2025 for the Phase 2 AD02 trial.","Trial uses XPro to target glial-driven neuroinflammation in early Alzheimer's.","Global, blinded, randomized Phase 2 trial; first doses administered to all patients.","CEO RJ Tesi cited overenrollment as a major accomplishment for the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-098380","json":"https://secwatch.observer/filing/0001213900-24-098380.json","markdown":"https://secwatch.observer/filing/0001213900-24-098380.md","text":"https://secwatch.observer/filing/0001213900-24-098380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024098380/0001213900-24-098380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024098380/ea0221033-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:31:11.837820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}